Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor
RO4929097 works in treating patients with stage IV melanoma. Gamma-secretase/Notch signalling
pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.